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Abstract
Objective—To describe the epidemiology, risk factors, and in-hospital outcomes of tracheostomy 
in infants in the neonatal intensive care unit (NICU).
Study design—We analyzed an electronic medical record from 348 NICUs from 1997–2012, 
and evaluated the associations between infant demographics, diagnoses, and pre-tracheostomy 
cardio-pulmonary support with in-hospital mortality. We also determined the trends in use of 
infant tracheostomy over time.
Results—We identified 885/887,910 (0.1%) infants who received a tracheostomy at a median 
postnatal and postmenstrual age of 72 days (25th, 75th percentile 27, 119) and 42 weeks (39, 46) 
respectively. The most common diagnoses associated with tracheostomy were bronchopulmonary 
dysplasia [396/885 (45%)], other upper airway anomalies [202/885 (23%)], and laryngeal 
anomalies [115/885 (13%)]. In-hospital mortality after tracheostomy was 125/885 (14%). On 
adjusted analysis, gestational age (GA) near term, small for gestational age (SGA) status, 
pulmonary diagnoses, number of days of FiO2>0.4, and inotropic support before tracheostomy 
were associated with increased in-hospital mortality. The proportion of infants requiring 
tracheostomy increased from 0.01% in 1997 to 0.1% in 2005 (P<0.001), but has remained stable 
since.
Address for correspondence: Christoph P. Hornik, MD, MPH, Duke Clinical Research Institute, Box 17969, Durham, NC 27715; ; 
Email: christoph.hornik@duke.edu; Phone: 919-668-8935; Fax: 919-668-7058 
The other authors declare no conflicts of interest.
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our 
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of 
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be 
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
HHS Public Access
Author manuscript
J Pediatr. Author manuscript; available in PMC 2017 June 01.
Published in final edited form as:
J Pediatr. 2016 June ; 173: 39–44.e1. doi:10.1016/j.jpeds.2016.01.072.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Conclusions—Tracheostomy is uncommonly performed in hospitalized infants, but the 
associated mortality is high. Risk factors for increased in-hospital mortality after tracheostomy 
include GA near term, SGA, and pulmonary diagnoses.
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database; infants; mechanical ventilation; mortality; neonates; tracheostomy
Tracheostomy may be required in infants with lung disease, airway anomalies, or 
neurologic, cardiac, or other diseases. With improved survival of extremely preterm infants, 
the number of infant tracheostomies is expected to increase, although this trend has not yet 
been demonstrated in the literature.1,2
Epidemiologic data on infant tracheostomy are mostly limited to single-center studies,3,4 
which focus on premature infants, with particular emphasis on those with 
bronchopulmonary dysplasia (BPD).4-6 Data regarding tracheostomy and outcomes in other 
infant populations are limited, as are data on risk factors associated with outcomes following 
tracheostomy. The few existing studies evaluating risk factors include predominantly older 
children, focus on the postnatal age at tracheostomy, and report different clinical outcomes. 
One study found that tracheostomy performed later in life was associated with need for 
home ventilation and gastrostomy tube placement, and a second observed an increased 
association between death and neurodevelopmental outcomes.7,8 Risk factors associated 
with poor outcomes specifically in infants have not been completely reported.
The objectives of this retrospective multicenter study are to describe the epidemiology of 
tracheostomy in infants admitted to neonatal intensive care units (NICUs) and to identify 
risk factors associated with in-hospital mortality following tracheostomy.
Methods
We used an electronic medical record from a clinical data warehouse that prospectively 
captures information on infants cared for by the Pediatrix Medical Group in 348 NICUs in 
North America. Data on multiple aspects of care are entered into a shared electronic record 
to generate admission and daily progress notes, and discharge summaries. Information 
regarding maternal history, demographics, medications, laboratory results, diagnoses, and 
procedures is then transferred to the data warehouse for quality improvement and research 
purposes.9
We included all infants who underwent tracheostomy during their initial hospitalization at 
one of 348 NICUs managed by the Pediatrix Medical Group between 1997 and 2012. Infants 
with missing information on postnatal age at tracheostomy and those with unknown 
discharge status were excluded. We extracted data on all days of hospitalization in the 
NICU. This study was approved by the Duke University Institutional Review Board without 
the need for written informed consent because the data were collected without identifiers.
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Definitions
We reviewed all infant diagnoses associated with tracheostomy to identify possible 
indications for tracheostomy. We grouped diagnoses of interest into airway, pulmonary, 
neuromuscular, and central nervous system (CNS) categories. Airway diagnoses included 
vocal cord paralysis, laryngeal anomalies (atresia, webs, stenosis, or malacia), subglottic 
stenosis, tracheobronchomalacia, or other upper airway anomalies (macro- or micrognathia, 
macroglossia, choanal stenosis or atresia, nasal atresia, or other upper airway obstruction). 
Pulmonary diagnoses included pulmonary hypoplasia, BPD, chronic aspiration, congenital 
diaphragmatic hernia, tracheoesophageal fistula, or other pulmonary anomalies. Given the 
association between BPD and several of the diagnoses considered as possible tracheostomy 
indications, BPD was considered to be a possible indication for tracheostomy only if another 
possible indication for tracheostomy was not present. In those cases where there was another 
possible indication, BPD was only considered a comorbidity and not listed as a possible 
indication. We classified infants <32 weeks gestational age (GA) as having BPD if they 
received supplemental oxygen or respiratory support (nasal cannula, continuous positive 
airway pressure, or mechanical ventilation) continuously from a postmenstrual age of 36 
0/7-36 6/7 weeks. We classified infants ≥32 weeks GA as having BPD if they received 
supplemental oxygen or respiratory support (nasal canula, continuous positive airway 
pressure, or mechanical ventilation) continuously from a postnatal age of 28-34 days.10 
Neuromuscular diagnoses included spinal muscular atrophy type 1, congenital muscular 
dystrophy, myasthenia gravis (including congenital), or other musculoskeletal anomalies. 
CNS diagnoses included hypoxic ischemic encephalopathy (HIE) and congenital CNS 
malformations. Because the database does not include a primary indication for 
tracheostomy, each indication variable listed above was coded as a binary (yes/no) variable, 
so an infant could have more than one possible diagnosis associated with tracheostomy. We 
defined congenital heart disease (CHD) as any cardiac malformation except patent ductus 
arteriosus and biscupid aortic valve (Table I; available at www.jpeds.com). Genetic 
syndromes were defined as any of the following diagnoses: trisomies (eg, trisomy 21, 18, 
13), genetic associations (eg, CHARGE, VACTERL), deletion syndromes (eg, 13q-, 5p-), 
and clinically relevant syndromes (e.g., DiGeorge syndrome, Treacher-Collins). We defined 
retinopathy of prematurity (ROP) as stage III or IV ROP, intraventricular hemorrhage (IVH) 
as grade III or IV IVH, supplemental oxygen as the need for fraction of inspired oxygen 
(FiO2) > 0.4, and mechanical ventilation as the need for conventional or high-frequency 
ventilation (HFV).
Our primary outcome of interest was in-hospital mortality. Secondary outcomes included 
duration of mechanical ventilation, time to wean to FiO2 < 0.4 and supplemental FiO2>0.21 
after tracheostomy, defined as time from tracheostomy to the first day off mechanical 
ventilation and the first day with an FiO2=0.21, respectively.
Statistical Analyses
We summarized continuous and categorical variables as medians with 25th and 75th 
percentiles and counts with proportions, respectively. We used Wilcoxon rank sum, Kruskal-
Wallis, chi-square, and Fisher exact tests to compare the study variables across groups, as 
appropriate. We evaluated trends in proportion of tracheostomies over time using the 
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Cochran-Armitage test for trend. For the risk factor analysis, we performed univariable 
logistic regression analysis for GA, birth weight, small for gestational age (SGA), male sex, 
ethnicity, presence of genetic syndromes, presence of CHD, BPD diagnosis, categories of 
possible indications for tracheostomy, postmenstrual age, postnatal age, and number of days 
on mechanical ventilation, HFV, inotropic support, and FiO2>0.4 prior to tracheostomy as 
predictors of in-hospital mortality. We classified GA into 5 a priori defined categories: ≤25; 
26-28; 29-32; 33-36 and ≥37 weeks and BW into 3 a priori defined categories: <1000; 
1000-1500; and >1500g. All variables significant in univariable analysis (P<0.05) were 
considered candidates for inclusion in the full model, and we used forward addition (P=0.15) 
and backward elimination (p=0.2) techniques to identify a reduced model. This reduced 
model was then inspected, and clinically relevant covariates that had been removed in the 
reduction steps were added back into the model. Following standard model assumption 
diagnostics including assessment of collinearity using variance inflating factors, the 
following variables remained in the final model: GA, SGA, male sex, postnatal age at 
tracheostomy, number of days requiring FiO2>0.4, and number of days requiring inotropic 
support prior to tracheostomy, airway indication for tracheostomy, pulmonary indication for 
tracheostomy, and quintiles of discharge year. Given concerns about the correlation between 
unobserved NICU-specific effects and the variables included in our models, we used mixed 
models with fixed effects for NICU to estimate the final model parameters. This approach 
allowed us to control for the effect of each individual NICU in the final model. We 
conducted an a priori defined sensitivity analysis of our final model limited to inborn infants. 
This was done to evaluate the potential for referral bias induced by including infants 
transferred from another NICU and for whom the entire hospital course before tracheostomy 
was not known.
We analyzed the data using STATA 13.1 (College Station, TX), and considered a P-value of 
<0.05 statistically significant.
Results
We identified 885/887,910 infants (0.1%) requiring tracheostomy, of whom 760/885 (86%) 
survived to NICU discharge (Table II). The proportion of infants requiring a tracheostomy 
initially increased over the course of our study from 0.01% in 1997 to 0.1% in 2005 
(p<0.001). This proportion remained relatively unchanged from 2005 to 2012, with 0.1% of 
infants receiving a tracheostomy in 2012. The median birth weight and GA were 1547 g 
(25th, 75th percentile: 749, 2765), and 31 weeks (26, 37), respectively. Median birth weight 
and GA were higher in survivors compared with non-survivors (1771 g [770, 2850] vs. 905 
g [610, 1680], P<0.001, and 33 weeks [26, 28] vs. 28 weeks [25, 34], P<0.001, respectively). 
The majority of infants (754/885 [85%]) suffered from at least one comorbidity. BPD was 
the most common comorbidity (680/885 [77%]) followed by CHD (175/885 [20%]) and 
ROP (113/885 [13%]).The most common diagnoses associated with tracheostomy were 
BPD (396/885 [45%]), upper airway anomalies (202/885 [23%]), and laryngeal anomalies 
(115/885 [13%]) (Table III). Among the 803/885 (91%) infants with known BPD status, 
concomitant upper airway anomalies were less common in those with BPD (44%) compared 
with those without BPD (65%), p<0.001.
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The median duration of any mechanical ventilation (conventional or HFV) prior to 
tracheostomy was 37 days (8, 84) (Table IV). Infants who survived after tracheostomy had 
shorter duration of mechanical ventilation prior to tracheostomy (32 days [6, 77] vs. 70 days 
[36, 114], P<0.01). Median duration of mechanical ventilation prior to tracheostomy was 
longer in infants with pulmonary diagnoses compared with those with airway, 
neuromuscular, or CNS diagnoses (64 days [29, 98] vs. 18 days [4, 61], 24 days [10, 47], 
and 24 days [9, 47], P<0.001, respectively). HFV was provided in 370/885 (41.8%) of 
infants, but was less frequently provided in those who survived compared with those who 
died (284/760 [37.4%] vs. 86/125 [68.8%], P<0.01). HFV was more frequently provided in 
infants with pulmonary diagnoses compared with those with airway, neuromuscular or CNS 
diagnoses (262/433 [61%] vs. 122/425 [29%], 7/26 [27%], and 16/76 [21%], P<0.001).
Median weight, postnatal age, and postmenstrual age on day of tracheostomy were 3206 g 
(2630, 3890), 72 days (27, 119), and 42 weeks (39, 46), respectively. There was no 
difference in median weight on day of tracheostomy between infants who survived 
compared with those who died (3205 g [2650, 3875] vs. 3290 g [2486, 3943], P=0.84). 
However, the median postnatal and postmenstrual ages on the day of tracheostomy were 
lower in survivors compared with non-survivors (64 days [24, 111] vs. 114 days [81, 142], 
P<0.001, and 41 weeks [38, 45] vs. 44 weeks [42, 49], P<0.001, respectively). The median 
FiO2 requirement on day of tracheostomy was 0.3 (0.21, 0.41) and was lower in survivors 
compared with non-survivors (0.28% [0.21, 0.4] vs. 0.4 [0.3, 0.55], P<0.001).
A total of 125/885 infants (14%) died at a median of 114 days (81, 142) after tracheostomy. 
Median postnatal and postmenstrual ages on the day of death were 161 days (125, 207) and 
52 weeks (47, 57). Non-survivors died at a median of 45 days (18, 82) after tracheostomy. 
The survival rates in four diagnostic categories for tracheostomy were: airway (392/425 
[92.2%]), pulmonary (351/433 [81.1%]), neuromuscular (24/26 [92.3%]), and CNS (64/76 
[84.2%]). Survivors were discharged at a median of 40 days (22, 65) after tracheostomy. 
Median postnatal and postmenstrual ages on the day of discharge for survivors were 109 
days (61, 172) and 48 weeks (44, 54) respectively. The median total length of stay was 
shorter in survivors compared with non-survivors (98 [56, 167] vs. 152 [105, 200] days, 
P<0.001). After tracheostomy, 289/885 infants (32.7%) were never weaned off mechanical 
ventilation prior to discharge. This includes 93/289 infants (32%) who died on mechanical 
ventilation and 196/289 infants (68%) discharged on a home ventilator. Eighty-four of 769 
survivors (11%) were discharged on FiO2>0.4. For those infants who were weaned off 
mechanical ventilation for at least 1 day after tracheostomy, the median duration to freedom 
from mechanical ventilation was 6 days (3, 11). Weaning off oxygen to a FiO2=0.21 for at 
least 1 day after tracheostomy was successfully accomplished in 633/885 infants (72%). 
Median duration to wean to FiO2 < 0.4 was 2 days (2, 3). Median duration to wean off 
oxygen after tracheostomy was 3 days (2, 10). Survivors had a shorter median duration to 
wean off oxygen compared with non-survivors (3 days [2, 9] vs. 6 days [3, 17], P=0.002).
On adjusted analysis, GA 29-36 weeks (as opposed to those younger or older), SGA, 
pulmonary diagnoses, days of FiO2>0.4, and inotropic support before tracheostomy were 
independent risk factors for in-hospital mortality (Table V). Results were similar in a 
sensitivity analysis limited to inborn infants: with the exception of pulmonary diagnoses, 
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which was no longer associated with increased mortality, all other risk factors and their 
association with mortality following tracheostomy remained unchanged.
Discussion
We studied a large cohort of infants receiving tracheostomy and found that, overall, 
tracheostomy was rarely performed (0.1% of all NICU infants), but mortality in those 
requiring tracheostomy was high (14%) compared with mortality in all hospitalized infants 
in the Pediatrix database over the study period (2.5%). Pulmonary indications, moderate 
prematurity, SGA status, and surrogates for severity of illness prior to tracheostomy were 
associated with increased mortality.
The overall rate of tracheostomy in our study (0.1%) is lower than the 0.6–2.7% reported in 
previous studies.3,11 This is likely because we included all infants admitted to the NICU, and 
previous studies focused on low birth weight infants (<2500 g) or those with BPD.5,6,11,12 In 
a single-center study including all infants regardless of diagnosis or GA, tracheostomy rate 
was still higher than our cohort at 1.8%.3 The Pediatrix Clinical Data Warehouse, the data 
source for our study, represents a broad mix of NICUs of different acuity levels including 
academic medical centers and community hospitals, and may be a more accurate 
representation of the NICU population across the United States.9 We observed an increase in 
the proportion of infants requiring tracheostomy over the early years of our study, but no 
significant increase since 2005. The Neonatal Research Network report on very low birth 
weight infant survival from 2003 to 2007 showed that survival without morbidity, including 
survival without intubation, improved over this time period, and survival with BPD 
decreased.1 Further, use of prenatal steroids increased over the same time period. These 
findings may suggest that as interventions to prevent significant lung disease and BPD are 
implemented, the number of infants requiring tracheostomy may decrease.
The most common diagnoses associated with receipt of tracheostomy in our cohort were 
pulmonary diagnoses (48.9%). This is in contrast with findings from previous studies that 
reported upper airway anomaly was the most common indication for tracheostomy in infants 
and children.8,13 BPD was the most common diagnosis within the pulmonary diagnostic 
category that was associated with tracheostomy in our cohort (44%). This is consistent with 
a single-center study of 165 infants requiring tracheostomy in which BPD was the indication 
for tracheostomy in 58% of infants.3 In, 20% of infants requiring tracheostomy in our cohort 
had a diagnosis of CHD. These significant comorbidities may explain the high in-hospital 
mortality rate (14%) observed in our cohort. This finding is again consistent with previous 
studies, which have reported overall mortality rates ranging from 16% to 25%.3,8,12,14
We found that pulmonary diagnoses were associated with higher mortality, but airway 
diagnoses were not associated with mortality. Both the Pediatric Health Information Systems 
study and a review of the Kids Inpatient Database reported similar findings in children.13,15 
There are conflicting data regarding the association between GA and mortality after 
tracheostomy in infants. In a single-center study of 127 infants at 23–42 weeks GA with an 
overall mortality of 21%, higher GA was associated with higher mortality even after 
controlling for respiratory severity score (the product of mean airway pressure and FiO2) and 
Lee et al. Page 6
J Pediatr. Author manuscript; available in PMC 2017 June 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
postnatal age at tracheostomy.8 However, in the review of the Kids Inpatient Database of 
>18,000 hospitalizations of children requiring tracheostomy, prematurity, defined as a GA < 
36 weeks, was associated with increased mortality.15 In our cohort, only moderate and late
—not severe—prematurity was associated with increased risk of mortality when compared 
with full-term infants. We postulate that selection bias with overall lower survival of infants 
≤28 weeks GA to tracheostomy partly explains why mortality was not highest in this 
subgroup. Indeed, selection bias may explain the similar findings of another study involving 
793 infants with severe BPD that demonstrated increased risk of mortality in infants 28-32 
weeks GA compared with those <28 weeks GA.16 Regardless of this potential survival bias, 
it is worth noting that infants ≤28 weeks GA who survive to tracheostomy are not at 
significantly higher risk of mortality than full-term infants. In addition, we postulate that 
despite the high overall mortality rate reported in our study, tracheostomy may actually 
protect against mortality in an extremely high-risk population. It is imperative that future 
studies examine the impact of hospital course on long-term neurodevelopmental outcomes 
and identify steps to mitigate this risk.
The strengths of our study include its sample size and inclusion of a diverse group of 
NICUs. Our study is less likely to suffer from referral bias than previous single-center 
studies. The daily data collected in the Pediatrix Clinical Data Warehouse allowed to us 
provide a detailed description of infants requiring tracheostomy and to evaluate the 
association between diagnoses and other risk factors associated with receipt of tracheostomy 
and mortality. We did not, however, attempt to compare risk factors for mortality between 
infants with tracheostomy and those without tracheostomy. Our study is primarily limited by 
the fact that our data come from a shared electronic medical record and has not undergone 
the development and scrutiny of a prospective study database. We were, for example, not 
able to identify cause of death, which may or may not have been related to respiratory illness 
and tracheostomy itself. We also did not have any information on potential complications 
after tracheostomy, which may add significant morbidity for these medically complex 
infants. We attempted to control for severity of illness by including surrogate covariates in 
the multivariable model, but did not have data to more precisely identify the degree of 
respiratory compromise such as ventilator settings (positive end expiratory pressure) or 
mean airway pressure. Finally, we can comment only on diagnoses associated with 
tracheostomy, as the actual indication for the surgical procedure was not captured in the 
database.
In conclusion, we found that tracheostomy was rarely performed in infants but was 
associated with significant mortality. We identified several risk factors for mortality after 
tracheostomy in adjusted analysis, including moderate prematurity, SGA status, and 
pulmonary diagnoses. We did not identify a significant association between postnatal age at 
tracheostomy and mortality. Our study supports the notion that tracheostomy is associated 
with high mortality in infants, primarily in those with severe pulmonary disease. Future 
studies are needed to identify additional strategies that can mitigate the risk associated with 
tracheostomy, including infant selection for and timing of the procedure.
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BPD bronchopulmonary dysplasia
GA gestational age
NICU neonatal intensive care unit
SGA small for gestational age
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Table I
Congenital heart disease diagnoses in our cohort of infants
Cardiac Diagnosis Number of infants (%)
Atrial septal defect 87 (41.1)
Ventricular septal defect 81 (38.2)
Pulmonary valve stenosis 20 (9.4)
Double outlet right ventricle 4 (1.9)
Aoritc valve stenosis 2 (0.9)
Transposition of great vessels 2 (0.9)
Atrioventricular septal defect 2 (0.9)
Pulmonary artery atresia 1 (0.5)
Total anomalous pulmonary venous return 1 (0.5)
Ebstein anomaly 1 (0.5)
Others/Unclassified 11 (5.2)
Total 212 (100)
More than 1 defect was recorded for some infants.
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Table II
Subject demographics
All Survived Died
PaN=885, n (%) N = 760, n (%) N = 125, n (%)
Gestational age (weeks) <0.001
≤25 215 (24.2) 176 (23.2) 39 (31.2)
26–28 149 (16.8) 119 (15.7) 30 (24.0)
29–32 101 (11.4) 80 (10.5) 21 (16.8)
33–36 148 (16.7) 130 (17.1) 18 (14.4)
≥37 272 (30.7) 255 (33.6) 17 (13.6)
Birth weight (g) <0.001
<1000 339 (38.3) 272 (35.8) 67 (53.6)
1000–1500 98 (11.1) 80 (10.5) 18 (14.4)
>1500 448 (50.6) 408 (53.7) 40 (32.0)
Male 508 (57.6) 424 (55.9) 84 (67.7) 0.01
Race/ethnicity 0.002
White 374 (43.5) 332 (45.1) 42 (34.4)
Black 232 (27.0) 182 (24.7) 50 (40.1)
Hispanic 219 (25.5) 192 (26.1) 27 (22.1)
Others 34 (4.0) 31 (4.2) 3 (2.5)
Inborn 508 (59.0) 433 (58.8) 75 (60.5) 0.72
Comorbidities
CHD 175 (19.7) 144 (18.9) 31 (24.8) 0.24
ROP 113 (37.0) 88 (11.6) 25 (20.0) 0.002
BPDb 680 (76.9) 579 (76.1) 101 (80.8) 0.03
Genetic anomaly 100 (11.3) 87 (11.5) 13 (10.4) 0.73
IVH 55 (6.2) 44 (5.8) 11 (8.8) 0.20
CHD: congenital heart disease; BPD: bronchopulmonary dysplasia; IVH: intraventricular hemorrhage grade III or IV.
a
P-values are from chi-square tests of association comparing the distribution of each variable between infants who survived and those who died.
b
BPD was considered a comorbid condition regardless of the presence of other diagnoses.
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Table III
Diagnoses associated with tracheostomy
All Survived Died
PaN = 885, n (%) N = 760, n (%) N = 125, n (%)
Airway 425 (48.0) 392 (51.6) 33 (26.4) <0.001
 Laryngeal anomaly 115 (13.0) 109 (14.3) 6 (4.8)
 Other upper airway anomaly 202 (22.8) 192 (25.3) 10 (8.0)
 Subglottic stenosis 29 (3.3) 28 (3.7) 1 (0.8)
 Tracheobronchomalacia 108 (12.2) 89 (11.7) 19 (15.2)
 Vocal cord paralysis 66 (7.5) 65 (8.6) 1 (0.8)
Pulmonary 433 (48.9) 351 (46.2) 82 (65.6) <0.001
 Aspiration 54 (6.1) 47 (6.2) 7 (5.6)
 CDH 17 (1.9) 12 (1.6) 5 (4.0)
 BPDb 396 (44.7) 320 (42.1) 76 (60.8)
 Pulmonary hypoplasia 40 (4.5) 29 (3.8) 11 (8.8)
 Other pulmonary anomaly 52 (5.9) 37 (4.9) 15 (12.0)
 TEF 28 (3.2) 25 (3.3) 3 (2.4)
Neuromuscular 26 (2.9) 24 (3.2) 2 (1.6) 0.34
 Muscular dystrophy 6 (0.7) 5 (0.7) 1 (0.8)
 Other musculoskeletal anomaly 19 (2.2) 18 (2.4) 1 (0.8)
 Werdnig-Hoffmann syndrome 1 (0.1) 1 (0.1) 0 (0)
CNS 76 (8.6) 64 (8.4) 12 (9.6) 0.66
 Congenital malformation 53 (6.0) 45 (5.9) 8 (6.4)
 HIE 23 (2.6) 19 (2.5) 4 (3.2)
CDH: congenital diaphragmatic hernia, BPD: bronchopulmonary dysplasia; TEF: tracheaesophageal fistula; CNS: central nervous system; HIE: 
hypoxic ischemic encephalopathy.
a
P-values are from chi-square tests of association separately comparing the distribution of each indication category between infants who survived 
and those who died.
b
BPD was considered an indication for tracheostomy only if other indications were absent.
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Table IV
Median (25th percentile, 75th percentile) duration of respiratory support before and after 
tracheostomy
Survived Died
PaN = 760 N = 125
Before tracheostomy
 Days of FiO2>40% 3 (0, 23) 26 (3, 79) <0.001
 Days of MV 32 (6, 77) 70 (36, 114) <0.001
 Days of HFV 13 (6, 27) 16 (6, 32) 0.45
After tracheostomy
 Days of FiO2>40% 1 (0, 7) 15 (4, 41) <0.001
 Days of MV 11 (4, 44) 39 (17, 68) <0.001
 Days of HFV 0 (0, 0) 2 (0, 10) <0.001
FiO2: fraction of inspired oxygen; MV: mechanical ventilation; HFV: high-frequency ventilation.
a
P-values are from Wilcoxon rank-sum tests comparing the distribution of each variable between infants who survived and those who died.
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Table V
Adjusted odds ratios (95% confidence interval) for mortality after neonatal tracheostomy
Odds Ratio (95% CI)
Gestational age, weeks
 ≤25 1.82 (0.62, 5.37)
 26–28 2.18 (0.76, 6.26)
 29–32 4.24 (1.48, 12.14)
 33–36 4.06 (1.59, 10.41)
 ≥37 Reference
Small for gestational age 1.90 (1.11, 3.29)
Male 1.37 (0.77, 2.26)
Postnatal age at tracheostomy 1.01 (0.99–1.01)1.01 (1.00, 1.01)
Days of inotrope prior to tracheostomy 1.05 (1.01, 1.10)
FiO2 > 40% before tracheostomy 1.01 (1.01, 1.02)
Airway diagnosis 0.70 (0.38, 1.30)
Pulmonary diagnosis 1.97 (1.06, 3.68)
MV: mechanical ventilation; FiO2: fraction of inspired oxygen.
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